Table 2.
Patient and clinical characteristcis of ROS1+ solid tumors
| All | NSCLC | Glioblastoma | Breast | Other | |
|---|---|---|---|---|---|
| N (%) | 259 | 204 (79%) | 18 (7%) | 7 (3%) | 30 (11%) |
| Age median (range) | 63 (18–89) | 65 (27–89) | 63 (41–89) | 60 (40–77) | 52.5 (18–80) |
| Male | 113 (44%) | 86 (42%) | 11 (61%) | 0 (0%) | 16 (53%) |
| Female | 146 (56%) | 118 (58%) | 7 (39%) | 7 (100%) | 14 (47%) |
| Sequencing methods | |||||
| Targeted RNA Archer (prior to 2019) | 55 (21%) | 49 (24%) | 4 (22%) | 1 (14%) | 1 (3%) |
| WTS (post 2019) | 204 (79%) | 155 (76%) | 14 (78%) | 6 (86%) | 29 (96%) |
| Mean junction read (SD) | 54.7 | 64 (107.8) | 32.2 (55.1) | 6.7 (5.2) | 25.6 (25.8) |
| Median TMB | 4 | 4 | 3 | 5 | 4 |